Regen BioPharma (RGBPP) Equity Average (2016 - 2025)
Regen BioPharma (RGBPP) has disclosed Equity Average for 12 consecutive years, with -$6.4 million as the latest value for Q4 2025.
- On a quarterly basis, Equity Average fell 17.97% to -$6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.4 million, a 17.97% decrease, with the full-year FY2025 number at -$5.7 million, down 11.41% from a year prior.
- Equity Average was -$6.4 million for Q4 2025 at Regen BioPharma, down from -$6.0 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of -$4.9 million in Q1 2023 to a low of -$43.3 million in Q1 2022.
- A 5-year average of -$10.5 million and a median of -$5.9 million in 2025 define the central range for Equity Average.
- Peak YoY movement for Equity Average: tumbled 507.09% in 2022, then soared 88.65% in 2023.
- Regen BioPharma's Equity Average stood at -$11.6 million in 2021, then surged by 44.41% to -$6.5 million in 2022, then rose by 19.93% to -$5.2 million in 2023, then decreased by 5.33% to -$5.4 million in 2024, then decreased by 17.97% to -$6.4 million in 2025.
- Per Business Quant, the three most recent readings for RGBPP's Equity Average are -$6.4 million (Q4 2025), -$6.0 million (Q3 2025), and -$5.8 million (Q2 2025).